ReviewDeutsches Arzteblatt international2025
Preventive Measures for Patients with an Elevated Genetic Risk for Gynecological Malignancies, in Particular Familial Breast and Ovarian Cancer.
Review in Deutsches Arzteblatt international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApproximately 70 550 women receive a diagnosis of breast cancer in Germany each year. Ovarian cancer is much rarer, with approximately 7180 new cases per year. A woman's individual risk of breast and ovarian cancer can be quantitatively estimated with tools that are available online; these are playing an increasingly important role in genetic counseling. Environmental factors, lifestyles, and discoveries in epigenetics all need to be taken into account. An understanding of potential preventive measures for patients at elevated genetic risk of gynecological malignancies is becoming increasingly important for precise counseling in clinical practice.
methodsWe conducted a literature search in PubMed up to September 2025, taking into account current guidelines on primary, secondary, and tertiary prevention for women at elevated genetic risk of gynecological malignancies, with a particular focus on familial breast and ovarian cancer.
resultsThe lifetime risk of breast cancer in women with a pathogenic variant of the BRCA1 or BRCA2 gene is approximately 70%. For ovarian cancer, it is approximately 44% and 17%, respectively. Primary prevention includes risk-reducing surgery such as mastectomy and oophorectomy/salpingectomy, as well as the use of certain preventive drugs. An intensified early detection program for breast cancer is a secondary prevention measure. Tertiary prevention includes the option of further risk-reducing measures, such as contralateral mastectomy and the use of PARP inhibitors, for women already under treatment for hereditary breast or ovarian cancer.
conclusionThis article highlights the wide range of preventive options available for hereditary gyne - cological malignancies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.